B Cell Subsets and Cellular Signatures and Disease Relapse in Lupus Nephritis
Open Access
- 10 September 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11
Abstract
Introduction: Renal relapses adversely affect the long-term outcomes of patients with lupus nephritis (LN), but the pathogenic mechanisms remain elusive. B cell signatures of miR-148a, BACH1, BACH2, and PAX5 expression are relevant to the regulation of B lymphocyte homeostasis. It is unknown whether B cell signature is related to the relapse of LN. Methods: We compared B lymphocyte subsets and cellular signatures during disease quiescence between LN patients with multiple relapses (MR, ≥3 LN relapses within 36 months) and those with no relapse (NR). Also, circulating B lymphocytes were isolated from treatment-naïve patients with active LN and treated with antagomir-148a in vitro to investigate the relationship between miR-148a, BACH1, BACH2, and PAX5. Results: MR patients (n = 19), when compared with NR (n = 14), showed significantly lower percentage of circulating naïve B cells and higher memory B cell-to-naïve B cell ratio. MR patients also showed higher miR-148a levels in sera and B cells, and lower BACH1, BACH2, and PAX5 expression in naïve and memory B cells. Antagomir-148a upregulated BACH1, BACH2, and PAX5 expression, and reduced B cell proliferation upon stimulation, in naïve and memory B cells isolated from treatment-naïve active LN patients. Conclusion: Altered B cell subsets and cellular signatures of miR-148a, BACH1, BACH2, and PAX5 may be associated with distinct patient phenotypes related to the risk of LN relapse.Keywords
Funding Information
- Health and Medical Research Fund
This publication has 53 references indexed in Scilit:
- B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis—Role in Pathogenesis and Effect of Immunosuppressive TreatmentsInternational Journal of Molecular Sciences, 2019
- Renal Flare as a Predictor of Incident and Progressive CKD in Patients with Lupus NephritisClinical Journal of the American Society of Nephrology, 2014
- The role of cytokines in the pathogenesis of systemic lupus erythematosus – from bench to bedsideNephrology, 2013
- Survival analysis and causes of mortality in patients with lupus nephritisNephrology Dialysis Transplantation, 2012
- Abnormalities of B cell subsets in patients with systemic lupus erythematosusJournal of Immunological Methods, 2011
- Mortality in systemic lupus erythematosusArthritis & Rheumatism, 2006
- Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus NephritisAnnals of Internal Medicine, 2001
- Treatment of diffuse proliferative lupus glomerulonephritis: A comparison of two cyclophosphamide-containing regimensAmerican Journal of Kidney Diseases, 2001
- “Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritisKidney International, 1996
- Therapy of Lupus NephritisNew England Journal of Medicine, 1986